



Alameda Alliance for Health

# FORMULARY UPDATE

**Effective 02/01/2025, unless indicated  
below under Committee Actions.**

## **Alameda Alliance for Health Pharmacy & Therapeutics (P&T) Committee Decisions**

The P&T Committee reviewed the efficacy, safety, cost, and utilization profiles of the following therapeutic categories and drug monographs at the December 17, 2024, meeting:

<b>Therapeutic/Monograph Class Reviews</b>	
<ul style="list-style-type: none"> <li>• Blood Glucose Test Strips class review</li> <li>• Calcium and Vitamin D class review</li> <li>• Osteoporosis Agents class review</li> <li>• Pulmonary Arterial Hypertension Agents class review</li> <li>• Urinary Tract Antispasmodics class review</li> </ul>	<ul style="list-style-type: none"> <li>• Topical Agents for Actinic Keratosis Class Review</li> <li>• Cobenfy Monograph New MRG: Cobenfy</li> </ul>

The P&T Committee approved the following modifications to the formulary for the Alliance's Group Care programs.

<b>Generic//Biosimilar Name &amp; Strength/Dosage Form</b>	<b>Brand Name</b>	<b>Committee Actions</b>
diclofenac sodium external gel 3 %	Solaraze External Gel 3%	Add to formulary (F) with Prior Authorization (PA)
vigabatrin oral solution 100 MG/ML	Vigafyde oral solution 100 MG/ML	Add to F with PA
patiromer sorbitex calcium packet 1 GM	Veltassa oral packet 1 GM	Add to F with Step Therapy (ST) and Quantity Limit (QL)
norethindrone acetate and ethinyl estradiol oral tablet disintegrating 1-0.02 MG	Femlyv oral tablet disintegrating 1-0.02 MG	Add to F
voxelotor oral tablet 500 MG	Oxbryta oral tablet 500 MG	Update to non-formulary (NF)
voxelotor oral tablet soluble 300 MG	Oxbryta oral tablet soluble 300 MG	Update to NF
voxelotor oral tablet 300 MG	Oxbryta Oral Tablet 300 MG	Update to NF
daprodustat oral tablet 1 MG	Jesduvrog oral tablet 1 MG	Update to NF
daprodustat oral tablet 2 MG	Jesduvrog oral tablet 2 MG	Update to NF
daprodustat oral tablet 4 MG	Jesduvrog oral tablet 4 MG	Update to NF
daprodustat oral tablet 6 MG	Jesduvrog oral tablet 6 MG	Update to NF
daprodustat oral tablet 8 MG	Jesduvrog oral tablet 8 MG	Update to NF
vadadustat oral tablet 150 MG	Vafseo oral tablet 150 MG	Add to F with PA
vadadustat oral tablet 300 MG	Vafseo oral tablet 300 MG	Add to F with PA

### PRIOR AUTHORIZATION GUIDELINE UPDATES

Urinary Incontinence Agents	Corticotropin
Growth Hormone	Isotretinoin capsules
Oral Anti-Fungals	New MRG: Ohtuvayre
New MRG: Cobenfy	New MRG: Nemluvio
New MRG: Yorvipath	New MRG: Ileal bile acid transporter inhibitors (IBATs)
Injectable Methotrexate	Immunizations
Botulinum Toxins A&B	Jesduvroq
Ocaliva	Vigabatrin (Sabril)
Oxbryta (voxelotor)	

### PRIOR AUTHORIZATION GUIDELINES REVIEWED (NO UPDATES)

Oral and Injectable Oncology Medications	Ranolazine (Ranexa, Aspruzyo)
Non-Formulary/Prior Authorization Required Medications	Temazepam (Restoril)
Step Therapy Exception	Testosterone Agents
Prior Authorization Exception	Thalomid (thalidomide)
Blood Glucose Testing Supplies	Topical Diclofenac
Butorphanol (Stadol NS)	Gattex (teduglutide)
Endari	Vesicular Monoamine Transporter 2 (VMAT2) Inhibitors
Diclofenac sodium (Solaraze) 3% gel	Otezla (apremilast) for Behcet Disease
Rapid-Acting Insulin	Rayaldee (calcifediol ER)
Long-Acting Basal Insulin	Korlym (mifepristone)
Gonadotropin Releasing Hormone (GNRH) Agonists	Tetracycline Antibiotics
Self-administered Disease Modifying Therapies (DMTs) for Multiple Sclerosis	Agents for graft versus host disease
dalfampridine (Ampyra)	Janus Kinase Inhibitors for Nonsegmental Vitiligo
Ophthalmic Anti-Inflammatory Agents	Budesonide Nebulization Solution (Pulmicort Respules)
Fentanyl Citrate	Lodoco
Proton Pump Inhibitors (PPIs)	Sohonos

**For questions, please contact the Alliance's Pharmacy Services department at:  
(510) 747-4541.**